Eli Lilly and Company’s oral GLP-1 pill Foundayo (orforglipron) wins U.S. Food and Drug Administration approval, delivering up to 12.4% weight loss and setting up competition with Wegovy’s oral version.
Written By: Karthik Teja Macharla, PharmD
Reviewed By: Pharmacally Editorial Team
Eli Lilly and Company has secured approval from the U.S. Food and Drug Administration for Foundayo™ (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight with weight-related comorbidities positioning it as a direct competitor to Wegovy’s oral formulation.
Foundayo introduces a non-injectable GLP-1 option that can be taken without food or water restrictions, addressing convenience and adherence barriers. The therapy will be available via LillyDirect from April 6, with broader rollout across retail pharmacies and telehealth platforms to follow.
The approval is primarily supported by the Phase 3 ATTAIN program. In ATTAIN-1 (NCT05869903), patients on the highest dose achieved a mean weight loss of 12.4% (27.3 pounds) at 72 weeks versus 0.9% with placebo, while overall weight reduction across participants reached 11.1% compared to 2.1% with placebo. ATTAIN-2, conducted in patients with type 2 diabetes, provided supportive efficacy and safety data, reinforcing the therapy’s broader clinical potential.
Beyond weight loss, Foundayo improved key cardiometabolic markers, including waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure.
Experts highlighted the practical value of an oral option. Deborah Horn, Director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston, emphasized that a once-daily pill without intake restrictions can improve flexibility and real-world use, while still delivering clinically meaningful weight loss.
From an access standpoint, David A. Ricks noted that GLP-1 uptake remains low due to barriers such as cost, stigma, and complexity, positioning Foundayo as a simpler, more accessible option designed for broader adoption.
Patient advocacy groups also underscored the importance of expanding treatment choice. Joe Nadglowski, President and CEO of the Obesity Action Coalition, stated that additional options like Foundayo can help tailor care to individual patient needs and long-term treatment journeys.
Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist, distinguishing it from peptide-based therapies. Discovered by Chugai and licensed by Lilly in 2018, it is also being studied across multiple indications, including type 2 diabetes.
Safety findings were consistent with the GLP-1 class, with gastrointestinal events such as nausea, diarrhea, and vomiting most commonly reported. A boxed warning highlights the risk of thyroid C-cell tumors, and co-administration with other GLP-1 therapies is not recommended.
In addition, Eli Lilly and Company’s orforglipron has shown continued momentum across its broader clinical program, maintaining weight loss in patients transitioning from Wegovy and Zepbound in the ATTAIN-MAINTAIN study, while also outperforming oral semaglutide in the ACHIEVE-3 trial further reinforcing its competitive positioning against Novo Nordisk in the emerging oral GLP-1 market.
Lilly has outlined access initiatives, with eligible commercially insured patients potentially paying as little as $25 per month, while self-pay pricing starts at $149 monthly.
With filings underway in more than 40 countries, Foundayo’s approval signals a shift toward oral GLP-1 therapies, setting up a competitive race in the emerging pill-based obesity treatment segment.
References
FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions, 01 April 2026, FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions | Eli Lilly and Company
A Study of Orforglipron (LY3502970) in Adult Participants with Obesity or Overweight with Weight-Related Comorbidities (ATTAIN-1), ClinicalTrials.gov ID NCT05869903, https://clinicaltrials.gov/study/NCT05869903
About the Writer
Karthik Teja Macharla, PharmD is a Pharm.D. graduate with a strong interest in clinical research, pharmacovigilance, and medical writing. In his words, he is passionate about converting complex medical information into clear, evidence-based scientific communication, committed to contributing to patient safety and advancing healthcare through accurate and impactful medical content.